This study presents a novel dual-target strategy for the treatment of advanced type 2 diabetes, particularly suitable for patients experiencing non-autonomous weight loss, suggesting that the metabolic disease field should place greater emphasis on the coordinated regulation of beta-cell protection and systemic metabolic homeostasis.
Literature Overview
The article titled 'Bispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial,' published in the journal Nature Communications, systematically investigates the efficacy and safety of the novel bispecific agonist PG-102 in models of advanced type 2 diabetes. By integrating db/db mouse models with a phase I trial in healthy volunteers, the study reveals that PG-102 achieves potent glucose control while avoiding cachectic weight loss through simultaneous activation of GLP-1R and GLP-2R receptors, representing a mechanistic breakthrough over traditional incretin-based therapies. Further analysis indicates that this molecule has unique advantages in receptor co-activation, beta-cell protection, and peripheral glucose utilization, highlighting its translational potential in patients with refractory diabetes.Background Knowledge
Currently, more than half of patients with type 2 diabetes fail to achieve guideline-recommended glycemic control targets (HbA1c < 7.0%), particularly in advanced stages often accompanied by non-autonomous weight loss and muscle wasting, indicating significant metabolic imbalance and beta-cell failure. Although GLP-1R agonists such as semaglutide and tirzepatide are widely used, they primarily rely on insulin secretion and often exacerbate weight loss, creating a therapeutic dilemma for patients already in a malnourished state. In addition, gastrointestinal adverse reactions lead to treatment discontinuation in up to 50% of patients within one year, underscoring the limitations of current therapies in terms of tolerability and maintenance of metabolic homeostasis. Although the GLP-2 receptor (GLP-2R) has long been considered to regulate only intestinal growth, recent studies have revealed its important roles in beta-cell protection, anti-inflammatory effects, and insulin sensitivity regulation, suggesting it as a complementary target to GLP-1R. However, simple combination of monospecific agonists may fail to achieve synergistic effects and carry a risk of excessive intestinal proliferation. Therefore, developing bispecific molecules with both GLP-1R and GLP-2R activity, while optimizing receptor activity ratios and pharmacokinetics, has become a key strategy to overcome current therapeutic challenges.
Research Methods and Experiments
The study employed db/db mice as a model of advanced type 2 diabetes, which exhibit severe hyperglycemia, beta-cell functional failure, and cachectic weight loss, closely mimicking the pathological features of human advanced T2D. PG-102 was administered every three days at various doses (15–120 nmol/kg) for 12 weeks to evaluate its effects on glucose levels, HbA1c, body weight, and islet morphology. It was directly compared with GLP-1R monotherapy (semaglutide) and dual receptor agonists (tirzepatide). In vitro experiments used INS-1 cells, 3T3-L1 adipocytes, and L6 myotubes to assess the effects of PG-102 on beta-cell protection, glucose uptake, and signaling pathways. Receptor co-localization and endocytic dynamics were analyzed via confocal microscopy in HEK293 cells. Following preclinical validation, a single-center, randomized, double-blind, placebo-controlled phase I multiple-ascending-dose trial was conducted in 24 healthy adults with BMI 25–30 kg/m², divided into three dose groups (15 mg, 30 mg, 30/60 mg), receiving weekly dosing to evaluate safety, pharmacokinetics, and oral glucose tolerance test (OGTT) responses.Key Conclusions and Perspectives
Research Significance and Prospects
This study introduces a novel paradigm for the treatment of advanced type 2 diabetes, emphasizing the importance of maintaining metabolic homeostasis and body composition beyond glycemic control. The dual-receptor mechanism of PG-102 not only enhances beta-cell protection but also achieves systemic metabolic improvement through GLP-2R-mediated peripheral glucose utilization and anti-inflammatory effects. This strategy is particularly suitable for elderly, lean, or sarcopenic T2D patients, filling a critical gap in current therapies. From a drug development perspective, the success of PG-102 validates the feasibility of bispecific receptor agonists, suggesting that future exploration of additional incretin receptor combinations (e.g., GIPR/GLP-2R) could further optimize efficacy and safety.
Conclusion
PG-102 represents a mechanistically innovative bispecific GLP-1/GLP-2 receptor agonist that demonstrates unprecedented glycemic control in models of advanced type 2 diabetes while avoiding the weight loss commonly induced by conventional therapies. By integrating beta-cell protection, peripheral glucose utilization, and anti-inflammatory effects, PG-102 not only overcomes the dual limitations of efficacy and tolerability associated with existing incretin-based therapies but also offers a precision treatment option for high-risk patients with non-autonomous weight loss. Its favorable safety profile and pharmacokinetic characteristics in phase I trials further support progression to larger clinical studies. From bench to bedside, the successful development of PG-102 highlights the immense potential of multi-target synergistic interventions in complex metabolic diseases, potentially reshaping the care paradigm for advanced T2D and shifting therapeutic goals from 'lowering glucose' to 'metabolic system restoration.' This study sets a new benchmark for mechanistic research and drug development in type 2 diabetes, suggesting that future efforts should place greater emphasis on the spatiotemporal dynamics of receptor co-activation and tissue-specific effects.
